Last $23.45 USD
Change Today +0.01 / 0.04%
Volume 228.2K
As of 3:48 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for emergent biosolutions inc (EBS)

Year over year, Emergent BioSolutions, Inc. has been able to grow revenues from $281.9M USD to $312.7M USD. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold, SGA expenses and income tax expenses. All of these improvements led to a bottom line growth from $23.5M USD to $31.1M USD.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Restated
Dec 31
2011
Restated
Dec 31
2012
Dec 31
2013
4 Year
Trend
Revenues286.2273.4281.9312.7
TOTAL REVENUES286.2273.4281.9312.7
Cost of Goods Sold136.4167.0166.3182.1
GROSS PROFIT149.8106.4115.6130.7
Selling General & Admin Expenses, Total72.573.376.079.5
OTHER OPERATING EXPENSES, TOTAL72.573.376.079.5
OPERATING INCOME77.333.139.651.2
Interest Expense----0.0--
Interest and Investment Income0.80.10.10.1
NET INTEREST EXPENSE0.80.10.10.1
Other Non-Operating Income (Expenses)-1.0-0.30.30.4
EBT, EXCLUDING UNUSUAL ITEMS77.132.940.051.7
Merger & Restructuring Charges-2.5-----7.2
Other Unusual Items, Total-1.2-1.0-7.9-1.2
In Process R&D Expenses-----9.6--
Insurance Settlements----1.7--
EBT, INCLUDING UNUSUAL ITEMS73.431.932.143.4
Income Tax Expense26.215.813.913.1
Minority Interest in Earnings4.56.95.40.9
Earnings from Continuing Operations47.216.118.130.3
NET INCOME51.723.023.531.1
NET INCOME TO COMMON INCLUDING EXTRA ITEMS51.723.023.531.1
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS51.723.023.531.1
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $23.45 USD +0.01

EBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr114.00 DKK 0.00
Bioporto A/S kr2.14 DKK -0.04
Celldex Therapeutics Inc $15.14 USD -0.33
PharmAthene Inc $2.11 USD +0.05
Veloxis Pharmaceuticals A/S kr1.86 DKK -0.01
View Industry Companies
 

Industry Analysis

EBS

Industry Average

Valuation EBS Industry Range
Price/Earnings 64.5x
Price/Sales 2.5x
Price/Book 1.8x
Price/Cash Flow 65.0x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.